Bowtie, Hong Kong's first virtual insurer[1], announces the strategic relocation of its headquarters to 68 Johnston Road, Wan Chai. Effective 1 February 2026, the building will be officially renamed “Bowtie Life Insurance Tower” (“Bowtie Tower”). Located in a prime and highly visible district, this milestone marks Bowtie's growth from a home-grown startup into Hong Kong's […]
JA Solar, a global leader in photovoltaic products and integrated energy solutions, announced the successful commissioning of a solar-plus-storage microgrid at a modern C&I facility in Sicily. This project represents a practical implementation of JA Solar's “PV+Storage+X” model – a flexible approach that combines solar generation and battery storage with specific industry applications (“X”) to
(SWX:BSLN.SW),(Boerse Stuttgart – Freiverkehr:BSLN),(Boerse Berlin – Freiverkehr:BSLN),(Boerse Frankfurt – Freiverkehr:BSLN),(Boerse Muenchen – Freiverkehr:BSLN), Allschwil, Switzerland, December 11, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today a partnership with Phare Bio Inc., Boston (USA), a biotech social venture
Basilea and Phare Bio enter partnership combining anti-infectives industry expertise with unique AI capabilities for the development of a novel antibiotic GlobeNewswire December 11, 2025 Allschwil, Switzerland, December 11, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today
(Copenhagen:ZEAL), Press release – No. 19 / 2025 Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health Zealand Pharma targets five launches, +10 clinical pipeline programs, and industry-leading cycle times from idea to clinic by 2030 Catalyst-rich 2026 with multiple clinical readouts, including Phase 2 data
Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health GlobeNewswire December 11, 2025 Press release – No. 19 / 2025 Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health Zealand Pharma targets five launches, +10 clinical pipeline
San Antonio, Texas–(Newsfile Corp. – December 11, 2025) – HIVE Digital Technologies Ltd. (TSXV: HIVE) (NASDAQ: HIVE) (FSE: YO0) (BVC: HIVECO) (the “Company” or “HIVE”), a diversified multinational digital infrastructure company, is expanding its Latin American capital-markets presence with a new listing on the Colombian Stock Exchange—one of the region’s deepest, broadest, and most institutionally
— Collaboration will combine Zealand Pharma's expertise in obesity and metabolic health with OTR Therapeutics' proprietary oral small-molecule platform and strong drug discovery capabilities, to discover and develop novel therapeutics for multiple targets in metabolic diseases — OTR Therapeutics will receive an initial upfront payment of USD 20 million, which may increase to USD 30
(BX Swiss AG:BIOV.SW), Ad hoc announcement pursuant to Art. 53LR BASEL, Switzerland, Dec. 11, 2025 (GLOBE NEWSWIRE) — BV100 Phase 3 in Ventilator Associated Bacterial Pneumonia initiated with first country submission completed and first patients to be dosed in the coming months – Phase 3 read-out expected in H2 2027 Significant value inflection points achieved
(Paris:SAN), Sanofi's Qfitlia and Cablivi approved in China, expanding care for rare diseases Qfitlia, the first antithrombin-lowering therapy for hemophilia, can offer consistent protection with as few as six injections a year Cablivi, the first Nanobody medicine, targets acquired/immune-mediated thrombotic thrombocytopenic purpura — a rare, life-threatening blood clotting disorder Paris, December 11, 2025. The National